ROBERT BAYE: Open Payments
NPI 1780607549 · SHREVEPORT, LA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,274 in 48 payments from 10 companies in 2025. Trend: 2023 $24 · 2024 $1,024 · 2025 $1,274
Food & beverage: $1,187Education: $87
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 11 | $319 |
| Regeneron Healthcare Solutions, Inc. | 6 | $302 |
| GlaxoSmithKline, LLC. | 9 | $178 |
| Genentech USA, Inc. | 6 | $147 |
| Novartis Pharmaceuticals Corporation | 6 | $104 |
| ARS Pharmaceuticals Operations, Inc. | 3 | $75 |
| GENZYME CORPORATION | 2 | $54 |
| Pharming Healthcare, Inc. | 2 | $43 |
| Verona Pharma, Inc. | 2 | $31 |
| CSL Behring | 1 | $21 |
Products named: DUPIXENT, TEZSPIRE, Xolair, NUCALA, NEFFY, Rhapsido, AIRSUPRA, RUCONEST.
Industry payments across LA — which companies pay providers there.
